• Scribe Therapeutics’ third-quarter 2026 net loss widened 52% from the previous quarter to $9.9 million.
• Collaboration revenue fell 16% quarter-on-quarter to $1.6 million due to lower reimbursable research and development activities under the Eli Lilly collaboration.
• Cash, cash equivalents and marketable securities rose to $174.2 million at September 30, providing funding into the first half of 2029.
• The ongoing Phase 1 trial of LDL-C-lowering therapy STX-1150 is expected to deliver initial clinical data in the first half of 2027.
• An expanded Sanofi collaboration provides access to the ELXR epigenetic silencing technology and extends the target-selection nomination period.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Scribe Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121605PRIMZONEFULLFEED9876782) on November 12, 2026, and is solely responsible for the information contained therein.